Hot Features
Überwachen Sie mehrere Echtzeitkurse von führenden Börsen wie NASDAQ, NYSE, AMEX, Bovespa und mehr.
Nurix Therapeutics Inc is a biopharmaceutical company focused on the discovery, development and commercialization of oral, small molecule therapies designed to modulate cellular protein levels as a novel treatment approach for cancer and immune disorders. The company's pipeline comprises targeted pr... Nurix Therapeutics Inc is a biopharmaceutical company focused on the discovery, development and commercialization of oral, small molecule therapies designed to modulate cellular protein levels as a novel treatment approach for cancer and immune disorders. The company's pipeline comprises targeted protein degraders of Brutons tyrosine kinase, or BTK, a B-cell signaling protein, and inhibitors of Casitas B-lineage lymphoma proto-oncogene-B, or CBL-B, an E3 ligase that regulates T cell activation. Its drug candidate from protein degradation portfolio, NX-2127, is an orally available BTK degrader for the treatment of relapsed or refractory B-cell malignancies. Its drug candidate from E3 ligase inhibitor portfolio, NX-1607, is an orally available CBL-B inhibitor for immuno-oncology indications. Mehr anzeigen
| Zeitraum † | Änderung | Änderung % | Handelsbeginn | Hoch | Niedrig | Durchsch. Volumen | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | -0.96 | -6.46900269542 | 14.84 | 15.51 | 13.54 | 855879 | 14.5227027 | CS |
| 4 | -5.23 | -27.367870225 | 19.11 | 19.35 | 13.54 | 742488 | 16.26013403 | CS |
| 12 | -6.52 | -31.9607843137 | 20.4 | 21.67 | 13.54 | 744886 | 18.38863057 | CS |
| 26 | -9.44 | -40.4802744425 | 23.32 | 29.56 | 13.54 | 810393 | 21.63339858 | CS |
| 52 | -1.88 | -11.9289340102 | 15.76 | 29.56 | 11.9 | 897224 | 19.27802579 | CS |
| 156 | 0.25 | 1.83418928833 | 13.63 | 29.56 | 4.22 | 615900 | 14.8156917 | CS |
| 260 | -6.37 | -31.4567901235 | 20.25 | 52.38 | 4.22 | 518743 | 18.45451241 | CS |
| Keine Diskussionen Gefunden. |
| Neuen Thread Erstellen |
Support: +44 (0) 203 8794 460 | support@advfn.de
Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen
Premium
